Feb 04, 2019 8:15am EST Avalon GloboCare CEO David Jin, M.D., Ph.D. to Co-Chair the “Status of Cellular Therapy in the Asia Pacific Rim” Session at the Annual Meetings of the Transplantation and Cellular Therapy (TCT) -- ASBMT and CIBMTR Tandem Meeting 2019
Jan 28, 2019 8:00am EST Avalon GloboCare and its Subsidiary Genexosome Technologies Announce Discovery and Development of World’s First Saliva-Based Exosomal Biomarker “miR-185” as Dual Diagnostic and Therapeutic Target for Oral Cancer
Jan 15, 2019 8:00am EST Avalon GloboCare CEO David Jin, M.D., Ph.D. to Chair and Speak at the Plenary Session of the 14th Annual World Stem Cell Summit
Jan 03, 2019 9:00am EST Avalon GloboCare Establishes Joint Venture with Arbele Limited to Co-develop Next-Generation Multi-Targeted CAR-T Cellular Immunotherapy
Dec 19, 2018 8:00am EST Avalon GloboCare to Ring the Nasdaq Stock Market Closing Bell on January 7, 2019 at 4:00 PM Eastern
Nov 13, 2018 9:05am EST Avalon GloboCare Provides Third Quarter 2018 Business Update; Reports 30% Increase in Revenues
Oct 15, 2018 8:00am EDT Avalon GloboCare Announces Grand Opening of Newly Renovated Headquarters in New Jersey
Oct 09, 2018 9:00am EDT Avalon GloboCare Teams Up with Weill Cornell Medicine to Co-develop Standardization of cGMP-Grade Exosome Isolation and Application of Tissue-Specific Exosomes
Sep 20, 2018 8:00am EDT Avalon GloboCare Commences Operation of its Core GMP Platform, Epicon Biotech, to Facilitate Clinical Development of Cellular Therapies